Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner

mBio

Volumn 7, Issue 5, 2016, Pages

  Mullarkey, Caitlin E ^a   Bailey, Mark J ^a   Golubeva, Diana A ^b   Tan, Gene S ^a   Nachbagauer, Raffael ^a   He, Wenqian ^a   Novakowski, Kyle E ^b   Bowdish, Dawn M ^b   Miller, Matthew S ^b   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HEMAGGLUTININ; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; REACTIVE OXYGEN METABOLITE; ANTIGEN ANTIBODY COMPLEX; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL POPULATION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; INNATE IMMUNITY; LEUKOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; CELLS, CULTURED; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; NEUTROPHILS; ORTHOMYXOVIRIDAE; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; RECEPTORS, FC;

EID: 84994423081     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01624-16     Document Type: Article

References (52)

1. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167-182. http://dx.doi.org/10.1038/nrd4529
2. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007
3. Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P. 2014. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88:2340-2343. http://dx.doi.org/10.1128/JVI.03183-13
4. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalkspecific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13
5. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-3442. http://dx.doi.org/10.1128/JVI.03004-13
6. Nachbagauer R, Miller MS, Hai R, Ryder AB, Rose JK, Palese P, García-Sastre A, Krammer F, Albrecht RA. 2016. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J Virol 90:3268-3273. http://dx.doi.org/10.1128/JVI.02481-15
7. Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F. 2015. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33:3314-3321. http://dx.doi.org/10.1016/j.vaccine.2015.05.038
8. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 2013. 1976 and 2009 H1N1 influenza virus vaccines boost antihemagglutinin stalk antibodies in humans. J Infect Dis 207:98-105. http://dx.doi.org/10.1093/infdis/jis652
9. Ellebedy AH, Krammer F, Li G-M, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spear-man P, Andrews SF, Wilson PC, García-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R. 2014. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccina-tion in humans. Proc Natl Acad Sci U S A 111:13133-13138. http://dx.doi.org/10.1073/pnas.1414070111
10. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. 2013. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med 5:198ra107. http://dx.doi.org/10.1126/scitranslmed.3006637
11. Li G-M, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng N-Y, Lee J-H, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta K, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109:9047-9052. http://dx.doi.org/10.1073/pnas.1118979109
12. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng N-Y, Lee J-H, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O’Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208:181-193. http://dx.doi.org/10.1084/jem.20101352
13. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sc i U S A 109:2573-2578. http://dx.doi.org/10.1073/pnas.1200039109
14. Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, Baker SF, Yang H, Martínez-Sobrido L, Treanor JJ, Subbarao K, Golding H, Topham DJ, Sangster MY. 2015. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis 212:1270-1278. http://dx.doi.org/10.1093/infdis/jiv210
15. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14
16. Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJWM, Kwaks T, Otterstrom JJ, Juraszek J, Van Oijen AM, Vogels R, Friesen RHE. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. http://dx.doi.org/10.1371/journal.pone.0080034
17. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc÷R interactions for protection against influenza virus in vivo. Nat Med 20:143-151. http://dx.doi.org/10.1038/nm.3443
18. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366:8-19. http://dx.doi.org/10.1016/j.jim.2010.12.016
19. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. 2001. Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381-7388. http://dx.doi.org/10.4049/jimmunol.166.12.7381
20. Mócsai A. 2013. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 210:1283-1299. http://dx.doi.org/10.1084/jem.20122220
21. Lim K, Hyun Y-M, Lambert-Emo K, Capece T, Bae S, Miller R, Topham DJ, Kim M. 2015. Neutrophil trails guide influenza-specific CD8 T cells in the airways. Science 349:aaa4352. http://dx.doi.org/10.1126/science.aaa4352
22. Brinkmann V, Zychlinsky A. 2007. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 5:577-582. http://dx.doi.org/10.1038/nrmicro1710
23. Tate MD, Brooks AG, Reading PC. 2008. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res 9:57. http://dx.doi.org/10.1186/1465-9921-9-57
24. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC. 2011. The role of neutrophils during mild and severe influenza virus in-fections of mice. PLoS One 6:e17618. http://dx.doi.org/10.1371/journal.pone.0017618
25. DiLillo DJ, Ravetch JV. 2015. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 3:704-713. http://dx.doi.org/10.1158/2326-6066.CIR-15-0120
26. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23:41-51
27. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725. http://dx.doi.org/10.1182/blood-2008-09-179754
28. Lundqvist H, Dahlgren C. 1996. Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radic Biol Med 20:785-792. http://dx.doi.org/10.1016/0891-5849(95)02189-2
29. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. 2012. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86:6179-6188. http://dx.doi.org/10.1128/JVI.00469-12
30. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza A virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281. http://dx.doi.org/10.1128/JVI.00969-13
31. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12
32. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 6:e1000745. http://dx.doi.org/10.1371/journal.ppat.1000745
33. Llewellyn D, de Cassan SC, Williams AR, Douglas AD, Forbes EK, Adame-Gallegos JR, Shi J, Pleass RJ, Draper SJ. 2014. Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome. J Leukoc Biol 95:369-382. http://dx.doi.org/10.1189/jlb.0513274
34. Tan GS, Lee PS, Hoffman RMB, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. 2014. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol 88:13580-13592. http://dx.doi.org/10.1128/JVI.02289-14
35. Moran TM, Monestier M, Lai AC, Norton G, Reale MA, Thompson MA, Schulman JL, Riblet R, Bona CA. 1987. Characterization of variable-region genes and shared crossreactive idiotypes of antibodies spe-cific for antigens of various influenza viruses. Viral Immunol 1:1-12. http://dx.doi.org/10.1089/vim.1987.1.1
36. He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS. 2015. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol 89:3610-3618. http://dx.doi.org/10.1128/JVI.03099-14
37. Tan PS, Gavin AL, Barnes N, Sears DW, Vremec D, Shortman K, Amigorena S, Mottram PL, Hogarth PM. 2003. Unique monoclonal antibodies define expression of Fc RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 170:2549-2556. http://dx.doi.org/10.4049/jimmunol.170.5.2549
38. Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martínez-Soria E, Petry F, Ravetch JV, Nishimura S, Izui S. 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol 181: 6664-6669. http://dx.doi.org/10.4049/jimmunol.181.9.6664
39. Aleyd E, Heineke MH, van Egmond M. 2015. The era of the immunoglobulin A Fc receptor FcγRI; its function and potential as target in disease. Immunol Rev 268:123-138. http://dx.doi.org/10.1111/imr.12337
40. Jönsson F, Mancardi DA, Kita Y, Karasuyama H, Iannascoli B, Van Rooijen N, Shimizu T, Daëron M, Bruhns P. 2011. Mouse and human neutrophils induce anaphylaxis. J Clin Invest 121:1484-1496. http://dx.doi.org/10.1172/JCI45232
41. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemag-glutinin stalk domain. mBio 1(1):1-9. http://dx.doi.org/10.1128/mBio.00018-10
42. Yassine HM, Boyington JC, McTamney PM, Wei C-J, Kanekiyo M, Kong W-P, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS. 2015. Hemagglutinin-stem nanopar-ticles generate heterosubtypic influenza protection. Nat Med 21: 1065-1070. http://dx.doi.org/10.1038/nm.3927
43. Impagliazzo A, Milder F, Kuipers H, Wagner M, Zhu X, Hoffman RMB, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kukrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radosevic K. 2015. A stable trimeric influenza hemagglu-tinin stem as a broadly protective immunogen. Science 349:1301-1306. http://dx.doi.org/10.1126/science.aac7263
44. Kanekiyo M, Wei C-J, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong W-P, Wang L, Nabel GJ. 2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102-106. http://dx.doi.org/10.1038/nature12202
45. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. 2016. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-610. http://dx.doi.org/10.1172/JCI84428
46. Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, Johnston A, Rockman S, Laurie K, Barr I, Reading P, Lichtfuss M, Kent SJ. 2016. Influenza-specific antibody-dependent phagocytosis. PLoS One 11:e0154461. http://dx.doi.org/10.1371/journal.pone.0154461
47. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. 2015. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162:160-169. http://dx.doi.org/10.1016/j.cell.2015.06.026
48. Kramski M, Stratov I, Kent SJ. 2015. The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS 29:137-144. http://dx.doi.org/10.1097/QAD.0000000000000523
49. DiLillo DJ, Ravetch JV. 2015. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161:1035-1045. http://dx.doi.org/10.1016/j.cell.2015.04.016
50. Taylor RP, Lindorfer MA. 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 20:444-449. http://dx.doi.org/10.1016/j.coi.2008.05.011
51. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-1669. http://dx.doi.org/10.1084/jem.20040119
52. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446. http://dx.doi.org/10.1038/74704